[1]张晓璇,魏依兰,于 宁,等.脑小血管病患者血清lncRNA BIRF，lncRNA FAL1表达水平与脑白质病变程度的相关性分析[J].现代检验医学杂志,2024,39(06):102-107.[doi:10.3969/j.issn.1671-7414.2024.06.017]
　ZHANG Xiaoxuan,WEI Yilan,YU Ning,et al.Correlation Analysis between Serum lncRNA BIRF and lncRNA FAL1 Levels Expression and Degree of White Matter Lesions in Patients with Cerebral Small Vessel Disease[J].Journal of Modern Laboratory Medicine,2024,39(06):102-107.[doi:10.3969/j.issn.1671-7414.2024.06.017]
点击复制

脑小血管病患者血清lncRNA BIRF，lncRNA FAL1表达水平与脑白质病变程度的相关性分析()
分享到：

《现代检验医学杂志》[ISSN:/CN:]

卷:
第39卷
期数:
2024年06期
页码:
102-107
栏目:
论著
出版日期:
2024-11-15

文章信息/Info

Title:
Correlation Analysis between Serum lncRNA BIRF and lncRNA FAL1 Levels Expression and Degree of White Matter Lesions in Patients with Cerebral Small Vessel Disease
文章编号:
1671-7414（2024）06-102-06
作者:
张晓璇; 魏依兰; 于 宁; 韩玥莹; 姚 雪; 刘 瑶; 窦志杰
（承德医学院附属医院神经内科，河北承德 067000）
Author(s):
ZHANG Xiaoxuan;  WEI Yilan;  YU Ning;  HAN Yueying;  YAO Xue;  LIU Yao;  DOU Zhijie
（Department of Neurology, Affiliated Hospital of Chengde Medical University, Hebei Chengde 067000, China）
关键词:
脑小血管病; 长链非编码RNA 脑缺血相关因子; 1 号染色体上的局部扩增lncRNA; 脑白质病变
分类号:
R743.9；R392.11
DOI:
10.3969/j.issn.1671-7414.2024.06.017
文献标志码:
A
摘要:
目的 探究脑小血管病（CSVD）患者血清长链非编码RNA（lncRNA）脑缺血相关因子（BIRF）、1 号染色体上的局部扩增lncRNA（lncRNA FAL1）表达与脑白质病变（WML）程度的相关性分析。方法 选取承德医学院附属医院2021 年6 月～ 2023 年6 月收治的102 例CSVD 患者，根据WML 诊断标准将CSVD 患者分为WML 组（n=72）和非WML 组（n=30）。并根据Fazekas 评分进一步将WML 组分为轻度WML 组（n=24）、中度WML 组（n=36）和重度WML 组（n=12）。采用实时荧光定量聚合酶链式反应（RT-qPCR）检测血清中lncRNA BIRF，lncRNA FAL1 水平；采用Pearson 相关分析血清lncRNA BIRF，lncRNA FAL1 水平的相关性。采用受试者工作特征（ROC）曲线分析血清lncRNA BIRF，lncRNA FAL1水平对CSVD患者发生重度WML的诊断价值。结果 WML组患者年龄（70.50±5.86 岁）、高血压史（有/ 无：43/29 例）、糖尿病史（有/ 无：45/27 例）、IL-33（68.35±6.80 pg/ml），IL-18（97.78±9.65 ng/L）、泛素羧基末端水解酶L1（UCH-L1）（0.29±0.10 μg/L），lncRNA BIRF 水平（2.45±0.30）显著高于非WML组（67.10±5.76岁，11/19 例，9/21 例，62.48±6.13 pg/ml，92.56±9.37 ng/L，0.24±0.06 μg/L，1.02±0.11）， 血清lncRNA FAL1 表达（0.52±0.10）显著低于非WML 组（1.04±0.15），差异具有统计学意义（t=2.683，4.518，8.978，4.085，2.510，2.550，25.346，20.500，均P ＜ 0.05）。轻度WML组、中度WML组、重度WML组CSVD患者血清lncRNA BIRF 水平（2.23±0.23，2.47±0.31，2.82±0.42）依次升高，血清lncRNA FAL1 水平（0.60±0.15，0.51±0.09，0.40±0.04）依次降低，差异具有统计学意义（F=14.913，13.899，均P ＜ 0.05）。Pearson 相关分析，WML 组患者血清lncRNA BIRF 与lncRNAFAL1 水平呈负相关（r= -0.603，P<0.001）；WML患者血清lncRNA BIRF 与Fazekas 评分呈正相关（r=0.483，P ＜ 0.001），血清lncRNA FAL1 与Fazekas 评分呈负相关（r= -0. 507，P ＜ 0.001）。血清lncRNA BIRF，lncRNA FAL1 水平单独及二者联合诊断CSVD 患者发生重度WML 的AUC（95%CI）分别为0.756 (0.641 ～ 0.850)，0.839 (0.733 ～ 0.915) 和0.892(0.796 ～ 0.953)，二者联合检测优于血清lncRNA BIRF 单独检测（Z=2.111，P=0.035）。结论 CSVD 伴WML 患者血清lncRNA BIRF 水平显著升高，lncRNA FAL1 水平显著降低，均与CSVD 患者WML 程度相关。
Abstract:
Objective To explore the correlation between the expression of long non-coding RNA (lncRNA) brain ischemiarelated factor (BIRF) and focally amplified lncRNA on chromosome 1 (lncRNA FAL1) in serum and the degree of white matter lesions (WML) in patients with cerebral small vessel disease (CSVD). Methods From June 2021 to June 2023, 102 CSVD patients admitted to Affiliated Hospital of Chengde Medical University were collected, and these patients were grouped into WML group (n=72) and non WML group (n=30) based on WML diagnostic criteria. According to the Fazekas score, the WML group was further grouped into mild WML group (n=24), moderate WML group (n=36) and severe WML group (n=12). Realtime fluorescence quantitative polymerase chain reaction (qRT-PCR) was applied to detect the levels of lncRNA BIRF and lncRNA FAL1 in serum. Pearson correlation was applied to analyze the correlation between serum lncRNA BIRF and lncRNA FAL1 levels. Receiver operating characteristic (ROC) curve was applied to analyze the diagnostic value of serum lncRNA BIRF and lncRNA FAL1 levels for severe WML in CSVD patients. Results The age (70.50±5.86 years), history of hypertension (Yes/No, 43/29), history of diabetes (Yes/No,45/27), IL-33 (68.35±6.80 pg/ml), IL-18 (97.78±9.65 ng/L), ubiquitin carboxyl terminal hydrolase L1 (UCH-L1) (0.29±0.10 μg/L) and lncRNA BIRF level (2.45±0.30) of patients in the WML group were higher than those in the non WML group (67.10±5.76 years, 11/19, 9/21, 62.48±6.13 pg/ml, 92.56±9.37 ng/L, 0.24±0.06 μg/L, 1.02±0.11), while the expression of serum lncRNA FAL1 (0.52±0.10) was lower than that in the non WML group (1.04±0.15), with significant differences (t=2.683, 4.518, 8.978, 4.085, 2.510, 2.550, 25.346, 20.500, all P<0.05). The serum lncRNA BIRF levels of CSVD patients in the mild, moderate and severe WML groups (2.23±0.23, 2.47±0.31, 2.82±0.42) were increased sequentially, while the expression of serum lncRNA FAL1（0.60±0.15, 0.51±0.09, 0.40±0.04）was decreased sequentially, with significant differences (F=14.913, 13.899, all P<0.05). Pearson correlation analysis, the serum levels of lncRNA BIRF and lncRNA FAL1 in patients with WML were negatively correlated (r= -0.603, P<0.001), serum lncRNA BIRF was positively correlated with Fazekas score in WML patients (r=0.483, P<0.001), but serum lncRNA FAL1 was negatively correlated with Fazekas score (r= -0.507, P<0.001). The AUCs of serum lncRNA BIRF and lncRNA FAL1 levels alone and both combination for predicting severe WML in CSVD patients were 0.756 (0.641 ～ 0.850), 0.839 (0.733 ～ 0.915) and 0.892 (0.796 ～ 0.953), respectively, and the combination of the two was superior to the detection of serum lncRNA BIRF alone (Z =2.111, P=0.035). Conclusion The serum lncRNA BIRF level is increased and lncRNA FAL1 is reduced in patients with CSVD and WML, and both are related to the degree of WML in CSVD patients.

参考文献/References:

[1] SANDSMARK D K, BASHIR A, WELLINGTON C L, et al. Cerebral microvascular injury: a potentially treatable endophenotype of traumatic brain injuryinduced neurodegeneration[J]. Neuron, 2019, 103(3): 367-379.
[2] REGENHARDT R W, DAS A S, OHTOMO R, et al. Pathophysiology of lacunar stroke: history’s mysteries and modern interpretations[J]. Journal of Stroke and Cerebrovascular Diseases, 2019, 28(8): 2079-2097.
[3] 赵继来, 胡玲玲, 刘勇, 等. 脑小血管病中脑白质病变严重程度的影响因素及其与阻塞性睡眠呼吸暂停低通气综合征的相关性研究[J]. 中国血液流变学杂志, 2022, 32(2): 217-221. ZHAO Jilai, HU Lingling, LIU Yong, et al. Influencing factors of the severity of white matter lesions and their correlation with obstructive sleep apnea-hypopnea syndrome[J]. Chinese Journal of Hemorheology, 2022,32(2): 217-221.
[4] CANNISTRARO R J, BADI M, EIDELMAN B H,et al. CNS small vessel disease: a clinical review[J]. Neurology, 2019, 92(24): 1146-1156.
[5] MARKUS H S, DE LEEUW F E. Cerebral small vessel disease: recent advances and future directions[J]. International Journal of Stroke, 2023, 18(1): 4-14.
[6] 李岳勇, 蒙兰青, 黄清, 等. 急性脑梗死发生过程中lncRNA TALNEC2 的作用与机制[J]. 安徽医科大学学报, 2022, 57(3): 366-373. LI Yueyong, MENG Lanqing, HUANG Qing, et al. The role and mechanism of lncRNA TALNEC2 in the occurrence of acute cerebral infarction[J]. Acta Universitatis Medicinalis Anhui, 2022, 57(3): 366-373.
[7] LI Shichao, ZHANG Lingyan, LIN Jiajie, et al. LncRNA BIRF promotes brain ischemic tolerance induced by cerebral ischemic preconditioning through upregulating GLT-1 via sponging miR-330-5p[J]. Molecular Neurobiology, 2022, 59(7): 3996-4014.
[8] GAO Mingqing, FU Jieting, WANG Yanqiang. The lncRNA FAL1 protects against hypoxia-reoxygenationinduced brain endothelial damages through regulating PAK1[J]. Journal of Bioenergetics and Biomembranes,2020, 52(1): 17-25.
[9] LITAK J, MAZUREK M, KULESZA B, et al. Cerebral small vessel disease[J]. International Journal of Molecular Sciences, 2020, 21(24): 9729.
[10] FAZEKAS F, CHAWLUK J B, ALAVI A, et al. Mr signal abnormalities at 1.5 T in Alzheimer’s dementia and normal aging[J]. American Journal of Roentgenology, 1987, 149(2): 351-356.
[11] 中国研究型医院学会脑小血管病专业委员会《中国脑小血管病诊治专家共识》编写组, 胡文立, 黄勇华,等. 中国脑小血管病诊治专家共识2021[J]. 中国卒中杂志, 2021, 16(7): 716-726. Cerebral Small Vessel Disease Professional Committee,Consensus Wrting Group, Chinese Research Hospital Association, HU Wenli, HUANG Yonghua, et al. Chinese consensus on diagnosis and therapy of cerebral small vessel disease 2021[J]. Chinese Journal of Stroke,2021, 16(7): 716-726.
[12] 冯雅晴, 任伯, 马原源, 等. 血清同型半胱氨酸及颈动脉斑块Crouse 积分与老年脑小血管病患者脑白质病变的相关性[J]. 中华老年心脑血管病杂志, 2023,25(6): 580-583. FENG Yaqing, REN Bai, MA Yuanyuan, et al. Correlation of serum homocysteine and carotid plaque Crouse score with cerebral white matter lesions in elderly patients with CSVD[J]. Chinese Journal of Geriatric Heart, Brain and Vessel Diseases, 2023, 25(6): 580-583.
[13] RASTOGI A, WEISSERT R, BHASKAR S M M. Emerging role of white matter lesions in cerebrovascular disease[J]. European Journal of Neuroscience, 2021, 54(4): 5531-5559.
[14] 李璐, 张颖, 张春丽, 等. 脑小血管病患者外周血Hcy,VILIP-1 和UA 水平与病情严重程度及认知障碍的相关性研究[J]. 现代检验医学杂志, 2022, 37(2): 173-178. LI Lu, ZHANG Ying, ZHANG Chunli, et al. Analysis of the correlation between peripheral blood Hcy,VILIP-1, UA and the severity of patients with cerebral small vessel disease and cognitive impairment[J]. Journal of Modern Laboratory Medicine, 2022, 37(2): 173-178.
[15] ZANON ZOTIN M C, SVEIKATA L, VISWANATHAN A, et al. Cerebral small vessel disease and vascular cognitive impairment: from diagnosis to management [J]. Current Opinion in Neurology, 2021, 34(2): 246-257.
[16] 丁联斌, 沈滔, 毛蕾, 等. 脑小血管病患者脑白质病变与血压昼夜节律的相关性研究[J]. 吉林医学,2021, 42(2): 317-319. DING Lianbin, SHEN Tao, MAO Lei, et al. Relationship between circadian rhythm of blood pressure and cerebral white matter lesions in patients with cerebral small vessel disease[J]. Jilin Medical Journal, 2021, 42(2): 317-319.
[17] ERENLER A K, BAYDIN A. Interleukin-33 (IL-33) as a diagnostic and prognostic factor in traumatic brain injury[J]. Emergency Medicine International, 2020,2020: 1832345.
[18] KORLEY F K, JAIN S, SUN Xiaoying, et al. Prognostic value of day-of-injury plasma GFAP and UCH-L1 concentrations for predicting functional recovery after traumatic brain injury in patients from the US TRACK-TBI cohort: an observational cohort study[J]. Lancet Neurology, 2022, 21(9): 803-813.
[19] ANG C E, TREVINO A E, CHANG H Y. Diverse lncRNA mechanisms in brain development and disease[J]. Current Opinion in Genetics & Development, 2020, 65: 42-46.
[20] MISHRA P, KUMAR S. Association of lncRNA with regulatory molecular factors in brain and their role in the pathophysiology of schizophrenia[J]. Metabolic Brain Disease, 2021, 36(5): 849-858.
[21] 来旭, 范亚楠, 余召师. 下调lncRNA FAL1 对甲状腺癌TPC-1 细胞功能的影响及其机制[J]. 标记免疫分析与临床, 2020,27(4):677-682. LAI Xu, FAN Ya’nan, YU Zhaoshi. Effects of downregulating lncRNA FAL1 on the function of thyroid cancer TPC-1 cells and its mechanism [J]. Labeled Immunoassays and Clinical Medicine, 2020,27 (4): 677-682.

相似文献/References:

[1]李　璐a,张　颖b,张春丽,等.脑小血管病患者外周血Hcy，VILIP-1和UA水平与病情严重程度及认知障碍的相关性研究[J].现代检验医学杂志,2022,37(02):173.[doi:10.3969/j.issn.1671-7414.2022.02.035]
　LI Lua,ZHANG Yingb,ZHANG Chun-li,et al.Analysis of the Correlation between Peripheral Blood Hcy, VILIP-1, UA and the Severity of Patients with Cerebral Small Vessel Disease and Cognitive Impairment[J].Journal of Modern Laboratory Medicine,2022,37(06):173.[doi:10.3969/j.issn.1671-7414.2022.02.035]
[2]郭晓敏a,雷向宇,刘宗伟,等.脑小血管病患者基于血液eGFR 和中性粒细胞/ 淋巴细胞比值水平构建发生认知功能障碍的列线图预测模型及评价[J].现代检验医学杂志,2024,39(05):85.[doi:10.3969/j.issn.1671-7414.2024.05.016]
　GUO Xiaomina,LEI Xiangyu,LIU Zongwei,et al.Construction and Evaluation of A Nomogram Prediction Model for Cognitive Impairment Based on Blood eGFR Levels and Neutrophil/Lymphocyte Ratio in Patients with Cerebral Small Vessel Disease[J].Journal of Modern Laboratory Medicine,2024,39(06):85.[doi:10.3969/j.issn.1671-7414.2024.05.016]

备注/Memo

备注/Memo:
基金项目：承德市应用技术研究与开发暨可持续发展议程创新示范区专项科技计划项目（202205B075）。
作者简介：张晓璇（1979-），女，本科，副主任医师，研究方向：缺血性脑血管病，E-mail：zhangxiao_197911@163.com。
更新日期/Last Update: 2024-11-15